Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?

Duygu Has ŞimşekSerkan KuyumcuSeyfullah KaradoganMelis OflasEmine Goknur IsikZeynep Gozde OzkanNail PaksoyOzgul EkmekciogluMeltem EkenelYasemin Sanli

Published in: Annals of nuclear medicine (2021)

Patients with high TV-PSMA had a significantly higher risk for DTX failure. PSMA-based tumor burden prior to DTX therapy seems to be a reliable predictive tool for survival in mCRPC patients.

Keyphrases

pet ct
pet imaging
end stage renal disease
newly diagnosed
squamous cell carcinoma
chronic kidney disease
small cell lung cancer
peritoneal dialysis
risk factors
computed tomography
radiation therapy
mesenchymal stem cells
combination therapy
locally advanced